| Santaram Vallurupalli, MD | |
|
920 Stanton L Young Blvd, Suite Wp 1380, Oklahoma City, OK 73104-5036 | |
| (405) 271-4426 | |
| (405) 271-3074 |
| Full Name | Santaram Vallurupalli |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 23 Years |
| Location | 920 Stanton L Young Blvd, Oklahoma City, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447412788 | NPI | - | NPPES |
| 121194 | Other | OH | STATE BOARD OF OHIO |
| 2008015178 | Other | MO | MEDICAL LICENSE |
| 30833 | Other | OK | OKLAHOMA MEDICAL BOARD |
| Facility Name | Location | Facility Type |
|---|---|---|
| O U Medical Center | Oklahoma city, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ou Health Partners Inc | 5991105876 | 779 |
News Archive
PGXL Labs, an internationally recognized pioneer in personalized medicine testing, announced today that it has established a collaborative partnership with AutoGenomics, Inc. wherein they will utilize the automated INFINITI® analyzer for several different personalized medicine applications.
Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.
One of the problems that cancer patients face is that many of the most potent anticancer therapies can be administered only by injection, which means that cancer patients must travel to receive their medication. But thanks to a new type of nanoparticle developed by researchers at the Johns Hopkins University School of Medicine, future cancer patients may be able to receive their medication in pill form.
In the study, published on the pre-print server medRxiv*, the researchers found a slight but significantly elevated risk of SARS-CoV-2 infection in households with young children between 10 months and five years old. However, recent exposure to human coronaviruses does not reduce the risk of SARS-CoV-2 infection in households with young children.
› Verified 6 days ago
| Entity Name | Board Of Regents Of The University Of Oklahoma - Ou Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801869250 PECOS PAC ID: 2860304334 Enrollment ID: O20031103000607 |
News Archive
PGXL Labs, an internationally recognized pioneer in personalized medicine testing, announced today that it has established a collaborative partnership with AutoGenomics, Inc. wherein they will utilize the automated INFINITI® analyzer for several different personalized medicine applications.
Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.
One of the problems that cancer patients face is that many of the most potent anticancer therapies can be administered only by injection, which means that cancer patients must travel to receive their medication. But thanks to a new type of nanoparticle developed by researchers at the Johns Hopkins University School of Medicine, future cancer patients may be able to receive their medication in pill form.
In the study, published on the pre-print server medRxiv*, the researchers found a slight but significantly elevated risk of SARS-CoV-2 infection in households with young children between 10 months and five years old. However, recent exposure to human coronaviruses does not reduce the risk of SARS-CoV-2 infection in households with young children.
› Verified 6 days ago
| Entity Name | Ou Health Partners Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528642642 PECOS PAC ID: 5991105876 Enrollment ID: O20210615000618 |
News Archive
PGXL Labs, an internationally recognized pioneer in personalized medicine testing, announced today that it has established a collaborative partnership with AutoGenomics, Inc. wherein they will utilize the automated INFINITI® analyzer for several different personalized medicine applications.
Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.
One of the problems that cancer patients face is that many of the most potent anticancer therapies can be administered only by injection, which means that cancer patients must travel to receive their medication. But thanks to a new type of nanoparticle developed by researchers at the Johns Hopkins University School of Medicine, future cancer patients may be able to receive their medication in pill form.
In the study, published on the pre-print server medRxiv*, the researchers found a slight but significantly elevated risk of SARS-CoV-2 infection in households with young children between 10 months and five years old. However, recent exposure to human coronaviruses does not reduce the risk of SARS-CoV-2 infection in households with young children.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Santaram Vallurupalli, MD 920 Stanton L Young Blvd, Suite Wp 1380, Oklahoma City, OK 73104-5036 Ph: (405) 271-4426 | Santaram Vallurupalli, MD 920 Stanton L Young Blvd, Suite Wp 1380, Oklahoma City, OK 73104-5036 Ph: (405) 271-4426 |
News Archive
PGXL Labs, an internationally recognized pioneer in personalized medicine testing, announced today that it has established a collaborative partnership with AutoGenomics, Inc. wherein they will utilize the automated INFINITI® analyzer for several different personalized medicine applications.
Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.
One of the problems that cancer patients face is that many of the most potent anticancer therapies can be administered only by injection, which means that cancer patients must travel to receive their medication. But thanks to a new type of nanoparticle developed by researchers at the Johns Hopkins University School of Medicine, future cancer patients may be able to receive their medication in pill form.
In the study, published on the pre-print server medRxiv*, the researchers found a slight but significantly elevated risk of SARS-CoV-2 infection in households with young children between 10 months and five years old. However, recent exposure to human coronaviruses does not reduce the risk of SARS-CoV-2 infection in households with young children.
› Verified 6 days ago
Dr. Kimberly S Smith, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 13100 N Western Ave Ste 200, Oklahoma City, OK 73114 Phone: 405-749-5025 Fax: 405-749-3585 | |
Mr. Nathan E Bradley, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 3301 N.w. 50th St, Oklahoma City, OK 73112 Phone: 405-947-0911 | |
Thomas Craddock Howard Iii, MD Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 9600 Broadway Ext, Oklahoma City, OK 73114 Phone: 405-230-9412 Fax: 405-230-9157 | |
Richard J Langerman Jr., DO Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 8100 S Walker Ave Bldg A, Oklahoma City, OK 73139 Phone: 405-632-4468 Fax: 405-632-0436 | |
Dr. Rishi Thakral, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 825 Ne 10th St, Oupb 1c, Oklahoma City, OK 73104 Phone: 405-271-2663 Fax: 405-271-6762 | |
Dr. William Austin Doss, DO Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 5401 N Portland Ave # 600, Oklahoma City, OK 73112 Phone: 405-713-9941 | |
Paul Alan Kammerlocher, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3115 Sw 89th St, Oklahoma City, OK 73159 Phone: 405-486-6900 Fax: 405-486-6839 |